Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FORUM MARKETS IncATNF · Entity 7020 | Director | December 03, 2020 | December 07, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FORUM MARKETS Inc
Report date December 03, 2020 · Filed December 07, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.49 · Expires 2030-12-03 | Direct | 25,000 |
Reported balance
After 2020-12-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-12-03 · Grant · Acquired 25,000 · Balance 25,000 F1: The Stock Options were granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F2: The options vest in equal monthly installments over the 12 months after the grant date (on the 3rd of each month), subject to the Reporting Person's continued service to the Company on such vesting dates. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2020-12-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Options were granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3.
F2: The options vest in equal monthly installments over the 12 months after the grant date (on the 3rd of each month), subject to the Reporting Person's continued service to the Company on such vesting dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 13,337 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.92 · Expires 2022-01-20 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.06 · Expires 2023-06-12 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 900 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-18 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-18 · Disposition to issuer · Disposed 1,454 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: This option was fully exercisable.
F3: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F4: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F5: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2020 Filed Dec 7, 2020 21:04 UTC | FORUM MARKETS Inc ATNF · Entity 7020 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001213900-20-041312 · ownership.xml · derivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-12-03 F1 · kind: The Stock Options were granted to the Reporting Person pursuant to the Issuer's 2020 Omnibus Incentive Plan. Exempt from Section 16(b) pursuant to Rule 16b-3. F2 · derivative.exercise_date: The options vest in equal monthly installments over the 12 months after the grant date (on the 3rd of each month), subject to the Reporting Person's continued service to the Company on such vesting dates. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 4,756 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 11 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 900 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 9 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 900 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 8 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 7 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $99.98 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 6 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $112.16 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 5 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 20,700 | $0.00 Strike: $88.50 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 4 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,700 shares Expires 2024-07-01 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 18,600 | $0.00 Strike: $59.06 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 3 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,600 shares Expires 2023-06-12 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $36.92 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-01-20 F3 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F2 · derivative.exercise_date: This option was fully exercisable. F3 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 13,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · nonDerivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| November 18, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 1,454 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001361 · form4-11222019_071102.xml · derivative · entry 10 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,454 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F5 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F5 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000727 · form4-06172019_040611.xml · derivative · entry 3 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,125 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: All restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: All restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 336 | $96.51 | $32,427.36 |
DisclosureSEC source: 0001415889-19-000727 · form4-06172019_040611.xml · nonDerivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,337 Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 1,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000727 · form4-06172019_040611.xml · nonDerivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000670 · form4-06052019_040646.xml · derivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000947 · form4-06182018_040601.xml · derivative · entry 3 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All of the restricted stock units granted to the reporting person on June 17, 2015 vested and such vested restricted stock units settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: All of the restricted stock units granted to the reporting person on June 17, 2015 vested and such vested restricted stock units settled for shares of the Company's common stock. F1 · derivative.expiration_date: All of the restricted stock units granted to the reporting person on June 17, 2015 vested and such vested restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 298 | $78.08 | $23,267.84 |
DisclosureSEC source: 0001415889-18-000947 · form4-06182018_040601.xml · nonDerivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,548 Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000947 · form4-06182018_040601.xml · nonDerivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: All of the restricted stock units granted to the reporting person on June 17, 2015 vested and such vested restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000936 · form4-06152018_010622.xml · derivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. The reporting person has elected to defer receipt of the first tranche of 484 shares until June 13, 2020. The other two tranches of shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. The reporting person has elected to defer receipt of the first tranche of 484 shares until June 13, 2020. The other two tranches of shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:14 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000936 · form4-06152018_010622.xml · derivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:29 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043760 · doc4.xml · derivative · entry 3 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:29 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Tax withholdingCommon Stock | 220 | $129.87 | $28,571.40 |
DisclosureSEC source: 0001209191-17-043760 · doc4.xml · nonDerivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,846 Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:29 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043760 · doc4.xml · nonDerivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,066 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040433 · doc4.xml · derivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F5 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F4 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. F4 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 16:04 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001209191-17-040433 · doc4.xml · derivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F2 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 14, 2018 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
| June 14, 2017 Filed Jun 20, 2017 16:06 UTC Amendment | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-041060 · doc4a.xml · derivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Underlying: Common Stock · 900 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F6 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F5 · derivative.exercise_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after June 14, 2020, at the reporting person's election to defer receipt of such shares. F5 · derivative.expiration_date: The restricted stock units will vest in three equal annual installments commencing on June 14, 2018. Vested shares will be delivered to the reporting person promptly after June 14, 2020, at the reporting person's election to defer receipt of such shares. Read SEC document |
| June 14, 2017 Filed Jun 20, 2017 16:06 UTC Amendment | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001209191-17-041060 · doc4a.xml · derivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,500 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F1 · security: This Form 4/A is being filed to amend and restate, in its entirety, the Form 4 filed on June 16, 2017 to indicate that the reporting person had elected to defer 100% of the RSUs listed in Table II to June 14, 2020. F3 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 14, 2018 or the day preceding the date of the next annual stockholder meeting. Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $36.92 | Not disclosed |
DisclosureSEC source: 0001209191-16-142764 · doc4.xml · derivative · entry 3 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2022-01-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The option was issued pursuant to the Company's 2008 Stock Incentive Plan (as amended and restated as of April 15, 2015). F2 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 20,000 | $110.82 | $2,216,400.00 |
DisclosureSEC source: 0001209191-16-142764 · doc4.xml · nonDerivative · entry 2 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,332 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $110.50 to $111.00, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| September 23, 2016 Filed Sep 26, 2016 16:08 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 20,000 | $36.92 | $738,400.00 |
DisclosureSEC source: 0001209191-16-142764 · doc4.xml · nonDerivative · entry 1 BARKER RICHARD W · CIK 0001255954 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,332 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.